Blockade of PVRIG reversed the exhaustion of both NK cells and CD8+ T cells; to further investigate the roles of NK cells and CD8+ T cells in the therapeutic blockade of PVRIG, we depleted NK cells or/and CD8+ T cells in tumor-bearing mice by treating them with depleting antibodies against NK cell receptor NK1.1 (PK136) and CD8β (53-5.8), respectively (Fig. 6a). Here, PVRIG is linked to neoplasm.